Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Analysis of genetically engineered oncolytic herpes simplex viruses in human prostate cancer organotypic cultures.

Passer BJ, Wu CL, Wu S, Rabkin SD, Martuza RL.

Gene Ther. 2009 Dec;16(12):1477-82. doi: 10.1038/gt.2009.94.

2.

Oncolytic virus therapy using genetically engineered herpes simplex viruses.

Todo T.

Front Biosci. 2008 Jan 1;13:2060-4. Review.

PMID:
17981691
4.

Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.

Kolodkin-Gal D, Edden Y, Hartshtark Z, Ilan L, Khalaileh A, Pikarsky AJ, Pikarsky E, Rabkin SD, Panet A, Zamir G.

Gene Ther. 2009 Jul;16(7):905-15. doi: 10.1038/gt.2009.44. Epub 2009 May 14.

PMID:
19440231
5.

Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.

Passer BJ, Castelo-Branco P, Buhrman JS, Varghese S, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2009 Jul;16(7):551-60. doi: 10.1038/cgt.2009.10. Epub 2009 Feb 6.

6.
7.

Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models.

Passer BJ, Cheema T, Wu S, Wu CL, Rabkin SD, Martuza RL.

Cancer Gene Ther. 2013 Jan;20(1):17-24. doi: 10.1038/cgt.2012.75. Epub 2012 Nov 9.

8.

Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.

Varghese S, Rabkin SD, Liu R, Nielsen PG, Ipe T, Martuza RL.

Cancer Gene Ther. 2006 Mar;13(3):253-65.

PMID:
16179929
9.

Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.

Maldonado AR, Klanke C, Jegga AG, Aronow BJ, Mahller YY, Cripe TP, Crombleholme TM.

J Gene Med. 2010 Jul;12(7):613-23. doi: 10.1002/jgm.1479.

PMID:
20603890
10.

MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.

Lee CY, Rennie PS, Jia WW.

Clin Cancer Res. 2009 Aug 15;15(16):5126-35. doi: 10.1158/1078-0432.CCR-09-0051. Epub 2009 Aug 11.

11.

Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.

Mahller YY, Sakthivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP, Mehrian-Shai R.

Cancer Gene Ther. 2008 Nov;15(11):733-41. doi: 10.1038/cgt.2008.40. Epub 2008 Jun 13.

12.

Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1.

Gaston DC, Odom CI, Li L, Markert JM, Roth JC, Cassady KA, Whitley RJ, Parker JN.

PLoS One. 2013 Nov 27;8(11):e81768. doi: 10.1371/journal.pone.0081768. eCollection 2013.

13.

An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.

Zeng WG, Li JJ, Hu P, Lei L, Wang JN, Liu RB.

Oncol Rep. 2013 Jun;29(6):2355-61. doi: 10.3892/or.2013.2359. Epub 2013 Mar 22.

PMID:
23525624
14.

Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.

Castelo-Branco P, Passer BJ, Buhrman JS, Antoszczyk S, Marinelli M, Zaupa C, Rabkin SD, Martuza RL.

Gene Ther. 2010 Jun;17(6):805-10. doi: 10.1038/gt.2010.20. Epub 2010 Mar 11.

15.

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy.

Li H, Nakashima H, Decklever TD, Nace RA, Russell SJ.

Cancer Gene Ther. 2013 Aug;20(8):478-85. doi: 10.1038/cgt.2013.43. Epub 2013 Jul 19.

17.

Oncolytic herpes simplex virus treatment of metastatic breast cancer.

Wang J, Hu P, Zeng M, Rabkin SD, Liu R.

Int J Oncol. 2012 Mar;40(3):757-63. doi: 10.3892/ijo.2011.1266. Epub 2011 Nov 21.

PMID:
22108767
18.

Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F.

Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14.

PMID:
19604626
19.

Oncolytic herpes simplex virus engineering and preparation.

Agarwalla PK, Aghi MK.

Methods Mol Biol. 2012;797:1-19. doi: 10.1007/978-1-61779-340-0_1. Review.

PMID:
21948465
20.

Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.

Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL.

Cancer Res. 2010 May 15;70(10):3890-5. doi: 10.1158/0008-5472.CAN-10-0155. Epub 2010 Apr 27.

Supplemental Content

Support Center